Search

everythinglearnresearchcommunity

for

Search:↓

Alopecia areata severity is influenced by factors like long disease duration, relapses, treatment response, and mental health, leading to the creation of a new severity measurement tool.

The STRIAA tool helps doctors quickly and effectively assess the severity of Alopecia Areata.

Screening for iron levels in patients with hair loss may help find a genetic iron overload condition early.

A 16-year-old boy's alopecia areata progressed unusually to resemble male pattern baldness.

AI can predict hair loss patterns to improve care and treatment.

The new tool helps measure the impact of alopecia areata on children's quality of life.

AI is revolutionizing healthcare by improving diagnosis, treatment, and monitoring, but still needs close supervision.

Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.

Researchers found a new mutation in the HR gene causing hair loss and skin bumps in a Pakistani family.

The ISHRS received high-level approval for its educational programs.

A new AIRE gene mutation causes rare autoimmune symptoms in a Lebanese boy.

Alopecia areata often starts before age 20, is more common in women, and may have a genetic link with other autoimmune diseases.

JAK inhibitors effectively reduce alopecia areata symptoms in Black patients.

A substance called VIP might protect hair follicles from being attacked by the immune system, and problems with VIP signaling could lead to hair loss in alopecia areata.

AH-001 could be a safer and more effective treatment for hair loss.

Alopecia areata greatly affects quality of life, especially mental health, and newer assessment tools better capture this impact than older ones.

People with alopecia areata may be more likely to have a certain type of hearing loss.

AUC and APL are distinct conditions needing careful clinical assessment.

Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.

Certain HLA class II alleles increase or decrease the risk of alopecia areata.

Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.

Vibration assisted analgesia reduces pain during corticosteroid therapy for alopecia.

Genetic testing for hairless gene mutations is crucial to correctly diagnose and treat atrichia with papular lesions.

Baricitinib effectively promotes long-term hair regrowth in alopecia areata patients.

A young girl had both alopecia areata and immune thrombocytopenic purpura at the same time, suggesting a possible link between the two.

Baricitinib works better in adolescents than adults for treating severe alopecia areata.

Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.

AI can help track and improve hair loss treatment outcomes.

Some people with heavy hair shedding might actually have a hidden form of alopecia, which can be identified by specific hair changes.

The document's content could not be processed.